Rivaroxaban and Standard Anticoagulants Safe, Reduce Clot Burden in Most Children With CVC-VTE
In most children with central venous catheter-related venous thromboembolism (CVC-VTE), treatment with rivaroxaban or other standard anticoagulants reduced clot burden, according to results from...
Study Supports Earlier, More Frequent Use of Hospice in Older Patients With Hematologic Malignancies
Earlier and more frequent hospice use may be associated with a lower probability of inpatient death and a reduction in aggressive care at end...
Examining Toxicities of CAR T-Cell Therapy in Patients With DLBCL
Chimeric antigen receptor (CAR) T-cell therapy has been an important addition to the treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)....
Early FVIII Prophylaxis Improves Long-Term Joint Outcomes in Severe Hemophilia A
Joint bleeding results in acute and chronic pain for patients living with severe hemophilia A, but joint outcomes improve when prophylactic factor VIII (FVIII)...
Methylprednisolone Augments IV Immune Globulin Response in Children With ITP
Intravenous immune globulin (IVIG) plus intravenous methylprednisolone (IVMP) confers a more rapid increase in platelet counts in children with immune thrombocytopenia (ITP), compared with...
Tisagenlecleucel Improves Patient-Reported Quality of Life in Relapsed/Refractory DLBCL
Treatment with tisagenlecleucel was associated with clinically meaningful improvements in health-related quality of life (QoL) over 18 months in patients with diffuse large B-cell...
High Bleeding Events in SCD Warrant Consideration of In-Hospital Ulcer Prophylaxis
By the time they reach age 40, 21% of patients with sickle cell disease (SCD) will have experienced a bleeding event, with most events...
Men Have More Published Research Than Women, Regardless of Caregiving Responsibilities
Previous research has shown that hematologists who participated in the American Society of Hematology’s (ASH’s) Clinical Research Training Institute (CRTI) experienced greater levels of...
Can Dasatinib Overcome the Negative Effects of KIT Mutations in Core Binding Factor AML?
A chemotherapy regimen of cytarabine and daunorubicin plus dasatinib was well tolerated in patients with previously untreated core binding factor acute myeloid leukemia (CBF-AML)...
Metabolic Syndrome Predicts Risk of Recurrent VTE in Patients With Newly Diagnosed DVT
Patients with newly diagnosed deep vein thrombosis (DVT) who have components of metabolic syndrome – hypertension, hyperlipidemia, diabetes mellitus, or obesity – have a...
Current Issue
October 2020 Volume 6, Issue 12
This issue examines racism in the U.S. health care system, discusses the FDA's newly loosened blood donation restrictions, and more.